Treatment of Intravenous Infiltration in a Neonate

Journal of Pediatric Health Care

Volumn 24, Issue 3, 2010, Pages 184-188

  Kuensting, Laura L ^a  

^a NONE

Author keywords

extravasation; hyaluronidase; Infiltration

Indexed keywords

ANTIINFECTIVE AGENT; HYALURONOGLUCOSAMINIDASE;

ARTICLE; CASE REPORT; CONTRAST MEDIUM EXTRAVASATION; FOOT; HUMAN; HYPERBILIRUBINEMIA; INFUSION; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEWBORN; PATHOLOGY; RISK FACTOR;

ANTI-BACTERIAL AGENTS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FOOT; HUMANS; HYALURONOGLUCOSAMINIDASE; HYPERBILIRUBINEMIA; INFANT, NEWBORN; INFUSIONS, PARENTERAL; INJECTIONS, INTRAVENOUS; INTENSIVE CARE UNITS, PEDIATRIC; MALE; RISK FACTORS;

EID: 77951112024     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pedhc.2010.02.001     Document Type: Article

References (30)

1. Allen C.H., Etzwiler L.S., Miller M.K., Maher G., Mace S., Hostetler M.A., et al., Harb G., for the INcreased Flow Utilizing Subcutaneously-Enabled-(INFUSE) Pediatric Rehydration Study Collaborative Research Group. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics 124 (2009) e859-e868
2. Baxter Healthcare Corporation. Hylenex (hyaluronidase human injection). [product information] (2009), Author, Deerfield, IL
3. Bertelli G., Dini D., Forno G.B., Gozza A., Silvestro S., Venturini M., et al., Pronzato P. Hyaluronidase as an antidote to extravasation of Vinca alkaloids: Clinical results. Journal of Cancer Research and Clinical Oncology 120 (1994) 505-506
4. Bookbinder L.H., Hofer A., Haller M.F., Zepeda M.L., Keller G.A., Lim J.E., et al., Frost G.I. A recombinant human enzyme for enhanced interstitial transport of therapeutics. Journal of Controlled Release 114 (2006) 230-241
5. Boyle D.M., and Engelking C. Vesicant extravasation: Myths and realities. Oncology Nursing Forum 22 (1995) 57-67
6. Cochran S.T., Bomyea K., and Kahn M. Treatment of iodinated contrast material extravasation with hyaluronidase. Academic Radiology 9 Suppl. 2 (2002) S544-S546
7. Dorr R.T., and Alberts D.S. Vinca alkaloid skin toxicity: Antidote and drug disposition studies in the mouse. Journal of the National Cancer Institute 74 (1985) 113-120
8. Dorr R.T., Snead K., and Liddil J.D. Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 78 (1996) 152-156
9. Ebo D.G., Goossens S., Opsomer F., Bridts C.H., and Stevens W.J. Flow-assisted diagnosis of anaphylaxis to hyaluronidase. Allergy 60 (2005) 1333-1334
10. Fullilove S., and Fixsen J. Major limb deformities as complications of vascular access in neonates. Paediatric Anaesthesia 7 (1997) 247-250
11. Guidance for industry: Pharmaceutical components at risk for melamine contamination. (2009). Retrieved from Food and Drug Administration website: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Gdances/default.htm
12. Heckler F.R. Current thoughts on extravasation injuries. Clinics in Plastic Surgery 16 (1989) 557-563
13. Heckler F.R., and McCraw J.B. Calcium-related cutaneous necrosis. Surgical Forum 27 (1976) 553-555
14. Humphrey G.B., Boon C.M.J., van Linden van den Heuvell G.F.E.C., and van de Wiel H.M. The occurrence of high levels of acute behavioral distress in children and adolescents undergoing routine venipunctures. Pediatrics 90 (1992) 87-91
15. Intravenous Nursing Society. Infiltration/extravasation. Journal of Intravenous Nursing 21 (1998) S36-S37
16. Kumar M.M., and Sprung J. The use of hyaluronidase to treat mannitol extravasation. Anesthesia & Analgesia 97 (2003) 1199-1200
17. Laurie S.W., Wilson K.L., Kernahan D.A., Bauer B.S., and Vistnes L.M. Intravenous extravasation injuries: The effectiveness of hyaluronidase in their treatment. Annals of Plastic Surgery 13 (1984) 191-194
18. Liu S.W., and Zane R. Peripheral intravenous access. In: Roberts J.R., and Hedges J.R. (Eds). Clinical procedures in emergency medicine. 4th ed (2004), Saunders, Philadelphia, PA 401-412
19. Loth T.S. Minimal surgical debridement for the treatment of chemotherapeutic agent-induced skin extravasations. Cancer Treatment Report 70 (1986) 401-404
20. Lund C.H., and Kuller J.M. Integumentary system. In: Kenner C., and Lott J.W. (Eds). Comprehensive neonatal care-an Interdisciplinary approach. 4th ed (2007), Saunders, Philadelphia, PA 65-91
21. Pirrello R.D., Ting Chen C., and Thomas S.H. Initial experiences with subcutaneous recombinant human hyaluronidase. Journal of Palliative Medicine 10 (2007) 861-864
22. Raszka Jr. W.V., Kueser T.K., Smith F.R., and Bass J.W. The use of hyaluronidase in the treatment of intravenous extravasation injuries. Journal of Perinatology 10 (1990) 146-149
23. Schulmeister L. Managing vesicant extravasations. Oncologist 13 (2008) 284-288
24. Schummer W., Schummer C., Bayer O., Muller A., Bredle D., and Karzai W. Extravasation injury in the perioperative setting. Anesthesia & Analgesia 100 (2005) 722-727
25. Schwartzman J. Hyaluronidase; a review of its therapeutic use in pediatrics. Journal of Pediatrics 39 (1951) 491-502
26. Szépfalusi Z., Nentwich I., Dobner M., Pillwein K., and Urbanek R. IgE mediated allergic reaction to hyaluronidase in paediatric oncological patients. European Journal of Pediatrics 156 (1997) 199-203
27. Thigpen J.L. Peripheral intravenous extravasation: Nursing procedure for initial treatment. Neonatal Network 26 (2007) 379-384
28. Thomas J.R., Yocum R.C., Haller M.F., and von Gunten C.F. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: The INFUSE-LR study. Journal of Palliative Medicine 10 (2007) 1312-1320
29. Yocum R.C., Kennard D., and Heiner L.S. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: A double-blind, placebo-controlled clinical trial. Journal of Infusion Nursing 30 (2007) 293-299
30. Zenk K.E., Dungy C.I., and Greene G.R. Nafcillin extravasation injury. Use of hyaluronidase as an antidote. American Journal of Diseases of Children 135 (1981) 1113-1114